{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:03:59Z","timestamp":1780095839299,"version":"3.54.0"},"reference-count":37,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian Research Agency","doi-asserted-by":"publisher","award":["P1-0170, L3-8203, and L3-2622"],"award-info":[{"award-number":["P1-0170, L3-8203, and L3-2622"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The early diagnosis of malignant mesothelioma (MM) could improve the prognosis of MM patients. To confirm an MM diagnosis, an immunohistochemical analysis of several tumor tissue markers, including calretinin, is currently required. Our aim is to evaluate serum calretinin as a potential biomarker in asbestos-related diseases, especially in MM. Our study includes 549 subjects: 164 MM patients, 117 subjects with asbestosis, 195 subjects with pleural plaques and 73 occupationally asbestos-exposed subjects without asbestos-related diseases. The serum calretinin concentration was determined with a commercially available enzyme immunoassay. Data on the soluble mesothelin-related peptides (SMRP) concentration are available from previous studies. MM patients had a significantly higher calretinin concentration than subjects without disease, subjects with pleural plaques or subjects with asbestosis (all p &lt; 0.001). The histological type was significantly associated with serum calretinin: patients with sarcomatoid MM had lower calretinin than patients with the epithelioid type (p = 0.001). In a ROC curve analysis, the area under the curve for calretinin concentration predicting MM was 0.826 (95% CI = 0.782\u20130.869; p &lt; 0.001). At the cutoff value of 0.32 ng\/mL, sensitivity was 0.683, while specificity was 0.886. The combination of calretinin and SMRP had the highest predictive value. Calretinin is a useful biomarker that can distinguish MM from other asbestos-related diseases and could, therefore, contribute to an earlier non-invasive diagnosis of MM.<\/jats:p>","DOI":"10.3390\/jcm10214875","type":"journal-article","created":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T22:06:16Z","timestamp":1635113176000},"page":"4875","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Serum Calretinin as a Biomarker in Malignant Mesothelioma"],"prefix":"10.3390","volume":"10","author":[{"given":"Cita","family":"Zupanc","sequence":"first","affiliation":[{"name":"Military Medical Unit\u2014Slovenian Army, 1000 Ljubljana, Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alenka","family":"Franko","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Clinical Institute of Occupational Medicine, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danijela","family":"\u0160trbac","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metoda","family":"Dodi\u010d Fikfak","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Clinical Institute of Occupational Medicine, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viljem","family":"Kova\u010d","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6707-6649","authenticated-orcid":false,"given":"Vita","family":"Dol\u017ean","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5673-4458","authenticated-orcid":false,"given":"Katja","family":"Gori\u010dar","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev-publhealth-031811-124704","article-title":"The Worldwide Pandemic of Asbestos-Related Diseases","volume":"34","author":"Stayner","year":"2013","journal-title":"Annu. Rev. Public Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.aogh.2016.01.019","article-title":"The Global Health Dimensions of Asbestos and Asbestos-Related Diseases","volume":"82","author":"Takahashi","year":"2016","journal-title":"Ann. Glob. Health"},{"key":"ref_3","first-page":"1519","article-title":"Impact of asbestos on public health: A retrospective study on a series of subjects with occupational and non-occupational exposure to asbestos during the activity of Fibronit plant (Broni, Italy)","volume":"7","author":"Villani","year":"2018","journal-title":"J. Public Health Res."},{"key":"ref_4","first-page":"64","article-title":"Mezoteliomi","volume":"16","author":"Kovac","year":"2012","journal-title":"Onkologija"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00063198-200307000-00004","article-title":"Benign asbestos pleural diseases","volume":"9","author":"Chapman","year":"2003","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.21037\/tlcr-19-488","article-title":"Does size matter?\u2014A population-based analysis of malignant pleural mesothelioma","volume":"9","author":"He","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2478\/v10019-012-0032-0","article-title":"Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients","volume":"46","author":"Kovac","year":"2012","journal-title":"Radiol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Johnen, G., Gawrych, K., Raiko, I., Casjens, S., Pesch, B., Weber, D.G., Taeger, D., Lehnert, M., Kollmeier, J., and Bauer, T. (2017). Calretinin as a blood-based biomarker for mesothelioma. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3375-5"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.21037\/tlcr.2019.11.29","article-title":"Application of immunohistochemistry in diagnosis and management of malignant mesothelioma","volume":"9","author":"Chapel","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1753466618808660","DOI":"10.1177\/1753466618808660","article-title":"Biomarkers in the diagnosis of pleural diseases: A 2018 update","volume":"12","author":"Porcel","year":"2018","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.21037\/tlcr.2018.10.04","article-title":"Malignant peritoneal mesothelioma: A review","volume":"7","author":"Broeckx","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ejso.2018.02.010","article-title":"Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study","volume":"44","author":"Bruno","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5301\/jbm.5000229","article-title":"Serum Mesothelin, Osteopontin and Vimentin: Useful Markers for Clinical Monitoring of Malignant Pleural Mesothelioma","volume":"32","author":"Bonotti","year":"2017","journal-title":"Int. J. Biol. Markers"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.21037\/jtd.2017.10.132","article-title":"Serum mesothelin and other biomarkers: What have we learned in the last decade?","volume":"10","author":"Cristaudo","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","article-title":"Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis","volume":"30","author":"Hollevoet","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Blum, W., Pecze, L., Rodriguez, J.W., Steinauer, M., and Schwaller, B. (2018). Regulation of calretinin in malignant mesothelioma is mediated by septin 7 binding to the CALB2 promoter. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4385-7"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"36256","DOI":"10.18632\/oncotarget.26332","article-title":"Calretinin promotes invasiveness and EMT in malignant mesothelioma cells involving the activation of the FAK signaling pathway","volume":"9","author":"Blum","year":"2018","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12931-015-0311-6","article-title":"Overexpression or absence of calretinin in mouse primary mesothelial cells inversely affects proliferation and cell migration","volume":"16","author":"Blum","year":"2015","journal-title":"Respir. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/ijc.28218","article-title":"Calretinin is essential for mesothelioma cell growth\/survival in vitro: A potential new target for malignant mesothelioma therapy?","volume":"133","author":"Blum","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lehnert, M., Weber, D.G., Taeger, D., Raiko, I., Kollmeier, J., Stephan-Falkenau, S., Br\u00fcning, T., Johnen, G., Brik, A., and Burek, K. (2020). Determinants of plasma calretinin in patients with malignant pleural mesothelioma. BMC Res. Notes, 13.","DOI":"10.1186\/s13104-020-05187-y"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Raiko, I., Sander, I., Weber, D.G., Raulf-Heimsoth, M., Gillissen, A., Kollmeier, J., Scherpereel, A., Bruning, T., and Johnen, G. (2010). Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of meso-thelioma patients. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-242"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.7150\/ijms.23939","article-title":"Biomarkers for predicting malignant pleural mesothelioma in a mexican population","volume":"15","author":"Pesch","year":"2018","journal-title":"Int. J. Med. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00408-019-00244-1","article-title":"Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma","volume":"197","author":"Casjens","year":"2019","journal-title":"Lung"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.5271\/sjweh.226","article-title":"Asbestos, asbestosis, and cancer: The helsinki criteria for diagnosis and attribution. Scand","volume":"23","author":"Tossavainen","year":"1997","journal-title":"J. Work. Environ. Health"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1164\/rccm.200310-1436ST","article-title":"Diagnosis and initial management of nonmalignant diseases related to asbestos","volume":"170","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_27","first-page":"261","article-title":"A Case Control Study of Lung Cancer and Exposure to Chrysotile and Amphibole at a Slovenian Asbestos-Cement Plant","volume":"51","author":"Fikfak","year":"2007","journal-title":"Ann. Occup. Hyg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/JOM.0b013e318065b855","article-title":"Glutathione s-transferases gstm1 and gstt1 polymorphisms and asbestosis","volume":"49","author":"Franko","year":"2007","journal-title":"J. Occup. Environ. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2478\/raon-2020-0011","article-title":"Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases","volume":"54","author":"Goricar","year":"2020","journal-title":"Radiol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"14321","DOI":"10.1038\/s41598-018-32315-3","article-title":"Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin\u2014A case-control comparison nested into a prospective cohort of asbestos-exposed workers","volume":"8","author":"Johnen","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_31","first-page":"14","article-title":"The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura","volume":"1","author":"Chirieac","year":"2011","journal-title":"Am. J. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5858\/arpa.2017-0092-OA","article-title":"Immunohistochemistry in peritoneal mesothelioma: A single-center experience of 244 cases","volume":"142","author":"Tandon","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_33","unstructured":"Pass, H.V.M., Cengel, K., Vachani, A., Carbone, M., Yang, H., Johnen, G., and Goparaju, C. (2021, October 19). Blood and fbln3: Be careful how and what you collect. In The International Mesothelioma Interest Group Programme Book; MS07.08; International Mesothelioma Interest Group; 2021. Available online: https:\/\/imig2021.org\/wp-content\/uploads\/2021\/05\/imig2021_Virtual_programmebook.pdf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e039079","DOI":"10.1136\/bmjopen-2020-039079","article-title":"Re-evaluation of potential predictors of calretinin and mesothelin in a population-based cohort study using assays for the routine application in clinical medicine","volume":"11","author":"Casjens","year":"2021","journal-title":"BMJ Open"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"32643","DOI":"10.1038\/srep32643","article-title":"Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo","volume":"6","author":"Greening","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/pmic.201200323","article-title":"Identification and characterization of proteins isolated from microvesicles derived from human lung cancer pleural effusions","volume":"13","author":"Park","year":"2013","journal-title":"Proteomics"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e017104","DOI":"10.1136\/bmjopen-2017-017104","article-title":"Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: Results from a population-based cohort study","volume":"7","author":"Casjens","year":"2017","journal-title":"BMJ Open"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/21\/4875\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:21:41Z","timestamp":1760167301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/21\/4875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":37,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["jcm10214875"],"URL":"https:\/\/doi.org\/10.3390\/jcm10214875","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]}}}